Lipocine Inc.

Theratech, Inc.

Other

Watson Pharmaceuticals, Inc.

Spriaso LLC

Srinivasan Venkateshwaran

Mahesh V Patel

Nachiappan Chidambaram

Chandrashekar Giliyar

Satish Kumar Nachaegari

Charles D Ebert

Basawaraj Chickmath

Danyi Quan

Joel Frank

David Fikstad

Chidambaram Nachiappan

Werner Heiber

Ninad A Deshpanday

Sonal R Patel

Feng-Jing Chen

Dinesh C Patel

William R Good

Uday Jain

Norman A Mazer

David T Fikstad

Suresh Borsadia

Chidambaram Machiappan

Daniel C Cheng

Steven L Krill

Amy Jo Portlock

Disclosed are bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-β)-Hydroxy-4-Androsten-3-one. Pharmaceutical compositions and the dosage forms of the bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters can be used to treat any condition associated with testosterone deficiency, including complete absence of endogenous testosterone in male or female subjects.

Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters

Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters

Described here are substantially pure (17-&#x3b2;)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof.

(17-&#xdf;)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use

The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37&#xb0; C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

17-hydroxyprogesterone ester-containing oral compositions and related methods

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Steroidal compositions

Disclosed are bioavailable solid state (17-&#x3b2;)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-&#x3b2;)-Hydroxy-4-Androsten-3-one.

Bioavailable solid state (17-&#x3b2;)-hydroxy-4-androsten-3-one esters

The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37&#xb0; C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

Testosterone undecanoate compositions

17-Hydroxyprogesterone ester containing oral compositions and related methods

The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone Cof at least 0.20 ng/mL.

Progesterone containing oral dosage forms and kits

17-hydroxyprogesterone ester containing oral compositions and related methods

Growing community of inventors

Salt Lake City, UT, United States of America

Srinivasan Venkateshwaran